Objectives: To assess efficiency of low dose 131 
INTRODUCTION:
Thyroid cancer is the most frequently occurring endocrine cancer, with more than 2100 new cases each year in the United Kingdom and more than 48,000 in the United States. (1) 
Randomization and Study Treatment:
Patients were randomly assigned to low-dose or high-dose radioiodine. All patients were instructed to follow a low-iodine diet for 3 weeks before ablation. Radioiodine ablation was recommended 1-4 months after surgery. Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%) (30).
Limitations of the Study:
The small number of evaluated patients showed non-significant higher success for thyroid ruminant ablation using high compared to low Radio -iodine dose. Also, some of the patients lost follow up after treatment; however this study is still ongoing for larger number of patients.
To conclude: The use of low RAI-131 ablative dose (30mCi) in patients with differentiated thyroid cancer who doesn't have gross residual disease of extra thyroidal metastasis after surgical treatment, may be effective as the high dose (100 mCi) ablation.
It's better to use low dose due to its lower cost, and to reduce the incidence and severity of RAI-131side effects & to skip the need for hospital admission foe isolation which has a high financial and psychological burden.
However, more studies with longer duration involving more patients are needed to determine that concern, especially in patients with intermediate risk group. 
